DJIA 18,053.71 23.50 0.13%
NASDAQ 4,806.86 33.39 0.70%
S&P 500 2,088.77 6.89 0.33%
market minute promo

GlaxoSmithKline (NYSE: GSK)

43.15 0.30 (0.70%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

GSK $43.15 0.70%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $42.97
Previous Close $42.85
Daily Range $42.90 - $43.29
52-Week Range $41.29 - $56.73
Market Cap $103.6B
P/E Ratio 14.73
Dividend (Yield) $2.45 (6.2%)
Ex-Dividend Date
Dividend Pay Date
11/05/14
01/08/15
Volume 1,985,462
Average Daily Volume 3,856,842
Current FY EPS $3.04

Sector

Healthcare

Industry

Drugs

GlaxoSmithKline (GSK) Description

The Company is a global healthcare group which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter medicines and health-related consumer products. Website: http://www.gsk.com/

News & Commentary Rss Feed

3 Pharma Giants Growing Significantly Faster Than GlaxoSmithKline PLC

GlaxoSmithKline is a common retirement holding, but there are three other big pharma stocks growing significantly faster that investors could choose from.

Novartis' Alcon's Travatan Obtains Label Expansion in the EU - Analyst Blog

BioCryst Rises on Positive Ebola Candidate Results - Analyst Blog

’Tis the season for buying stocks dumped for tax reasons

3 Clinical Stage Biotech Stocks That Should Be on Your Watchlist in 2015

Three Motley Fool analysts tell us which emerging biotechnology stocks they're watching in 2015.

3 Drugmakers Facing a Pivotal 2015

Isis Pharmaceuticals, PTC Therapeutics, and GW Pharmaceuticals all expect 2015 to be a pivotal year in their drive toward becoming commercially viable entities. Should investors jump in before the catalysts spark?

Overvalued Bonds Or Would You Buy Stocks With A PE Of 100?

The Most Disappointing Clinical Failures in 2014

Three Motley Fool contributors tell us what they think were the biggest drug trial failures this year.

Exciting News: A Game-Changing Shingles Vaccine Could Be On Its Way

GlaxoSmithKline plc has reported impressive late stage trial results for its shingles vaccine.

Tax-Loss Selling: 1 Stock We'd Be Glad to Sell Right Now

If you own any of these, it might be a good time to cut your losses and move on.

See More GSK News...

GSK's Top Competitors

GSK $43.15 (0.70%)
Current stock: GSK
JNJ $105.06 (0.45%)
Current stock: JNJ
NVS $94.10 (0.20%)
Current stock: NVS
RHHBY $34.23 (-0.16%)
Current stock: RHHBY